Technical Analysis for DERM - Dermira, Inc.

Grade Last Price % Change Price Change
grade C 10.5 -0.47% -0.05
DERM closed down 0.47 percent on Friday, May 17, 2019, on 26 percent of normal volume. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Down Flat
See historical DERM trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Shooting Star Candlestick Bearish 0.00%
180 Bearish Setup Bearish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -0.47%
Bollinger Band Squeeze Range Contraction -0.47%
Narrow Range Bar Range Contraction -0.47%
NR7 Range Contraction -0.47%
200 DMA Support Bullish 1.84%

Older signals for DERM ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Dermira, Inc., a specialty biopharmaceutical company, focuses on the development and commercialization of medical dermatology products to dermatologists and their patients primarily in the United States. The company's late-stage product candidates comprise Cimzia, an injectable biologic tumor necrosis factor-alpha inhibitor, which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04, a anticholinergic product that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01, a sebum inhibitor, which has completed a Phase IIa clinical trial for the treatment of acne. Its early-stage programs in preclinical development include DRM02, an inhibitor of phosphodiesterase-4 for the treatment of inflammatory skin diseases; and DRM05, a photodynamic therapy for the treatment of acne. Dermira, Inc. has a collaboration agreement with UCB Pharma S.A. for the development and commercialization of Cimzia. The company was formerly known as Skintelligence, Inc. and changed its name to Dermira, Inc. in September 2011. Dermira, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Medicine Biopharmaceutical Psoriasis Acne Immunosuppressants Dermatology Skin Cutaneous Conditions Hyperhidrosis Inflammatory Skin Diseases Treatment Of Inflammatory Skin Diseases
Is DERM a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 15.48
52 Week Low 5.9997
Average Volume 2,469,317
200-Day Moving Average 10.0896
50-Day Moving Average 11.5384
20-Day Moving Average 10.7955
10-Day Moving Average 10.548
Average True Range 0.6631
ADX 13.99
+DI 19.2217
-DI 19.824
Chandelier Exit (Long, 3 ATRs ) 9.9107
Chandelier Exit (Short, 3 ATRs ) 11.9093
Upper Bollinger Band 11.7062
Lower Bollinger Band 9.8848
Percent B (%b) 0.34
BandWidth 16.871845
MACD Line -0.3344
MACD Signal Line -0.3129
MACD Histogram -0.0215
Fundamentals Value
Market Cap 438.52 Million
Num Shares 41.8 Million
EPS -2.70
Price-to-Earnings (P/E) Ratio -3.89
Price-to-Sales 43.67
Price-to-Book 2.90
PEG Ratio -0.05
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 11.10
Resistance 3 (R3) 11.14 10.98 11.00
Resistance 2 (R2) 10.98 10.83 10.96 10.97
Resistance 1 (R1) 10.74 10.73 10.86 10.70 10.93
Pivot Point 10.58 10.58 10.64 10.56 10.58
Support 1 (S1) 10.34 10.43 10.46 10.30 10.07
Support 2 (S2) 10.18 10.33 10.16 10.03
Support 3 (S3) 9.94 10.18 10.00
Support 4 (S4) 9.90